SGLT2抑制剂与接受RAAS抑制剂患者的高钾血症风险
该研究为加拿大安大略省基于人群的回顾性队列研究(2015年7月1日至2021年6月30日),纳入66岁及以上、正在使用RAAS抑制剂且具有糖尿病或心衰病史、eGFR<45 mL/min/1.73 m2和/或尿白蛋白/肌酐比值>30 mg/mmol的成人。比较新处方SGLT2i者(20063例)与未启动SGLT2i的伪人群(19781例),采用倾向评分逆概率治疗加权平衡基线协变量。主要结局为1年内血清钾>5.5 mEq/L或高钾血症就诊编码,SGLT2i启动与高钾血症风险降低相关(HR 0.89,95%CI 0.82-0.96),且SGLT2i使用者RAASi停药率显著低于非使用者(36% vs 45%,P<.001)。结论认为在糖尿病、心衰或CKD且接受RAASi者中,SGLT2i启动与高钾血症及RAASi停药风险降低相关。
要点
- 在66岁及以上、使用RAASi且有糖尿病(95%)、心衰(17%)或CKD 3-5期(32%)者中,启动SGLT2i与1年内高钾血症风险降低相关(HR 0.89,95%CI 0.82-0.96)。
- SGLT2i使用者较非使用者RAASi停药率显著降低(36% vs 45%,P<.001)。
- 高钾血症定义为血清钾>5.5 mEq/L或索引日期后1年内因高钾血症的住院或门诊就诊编码。
- 该研究为基于人群的回顾性队列,采用倾向评分逆概率治疗加权平衡基线协变量,提示日常临床实践中SGLT2i启动可能减弱RAASi相关高钾血症风险。
适用人群与场景
- 加拿大安大略省66岁及以上成人,正在使用RAAS抑制剂,且具有糖尿病或心衰病史、eGFR<45 mL/min/1.73 m2和/或尿白蛋白/肌酐比值>30 mg/mmol。
- 队列中95%有糖尿病,17%有心衰,32%有CKD 3-5期。
诊断标准与关键阈值
- 高钾血症定义:血清钾>5.5 mEq/L,或索引日期后1年内因高钾血症的住院或门诊就诊行政编码。
研究设计与关键结果
- 研究类型:基于人群的回顾性队列研究,地点加拿大安大略省,时间2015年7月1日至2021年6月30日。
- 暴露组:新处方SGLT2i者20063例(平均[SD]年龄76.9[6.6]岁;男性12020例[59.9%]);对照组:未启动SGLT2i的伪人群19781例(平均[SD]年龄76.8[7.0]岁;男性11731例[59.3%])。
- 主要结局:SGLT2i启动与高钾血症风险降低相关(HR 0.89,95%CI 0.82-0.96)。
- 关键次要结局:SGLT2i使用者RAASi停药率显著低于非使用者(36% vs 45%,P<.001)。
证据类型、等级与局限
- 证据类型:基于人群的回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在糖尿病、心衰或CKD且接受RAASi者中,SGLT2i启动与高钾血症及RAASi停药风险降低相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Hyperkalemia is a common complication of taking a renin-angiotensin-aldosterone system inhibitor (RAASi). Post hoc analyses of large randomized clinical trials suggested that the addition of sodium-glucose cotransporter 2 inhibitors (SGLT2i) may attenuate this risk. It is unknown if this observation extends to daily clinical practice.
OBJECTIVE: To evaluate the association between SGLT2i initiation and hyperkalemia in individuals receiving RAASi with a background of diabetes, heart failure, or chronic kidney disease.
DESIGN, SETTING, AND PARTICIPANTS: This population-based retrospective cohort study was conducted in Ontario, Canada, from July 1, 2015, to June 30, 2021. The cohort comprised adults 66 years and older who were prescribed a RAASi and had a history of diabetes or heart failure, an estimated glomerular filtration rate of less than 45 mL/min/1.73 m2, and/or a urine albumin to creatinine ratio of greater than 30 mg/mmol. The data were analyzed between March 28, 2023, and March 22, 2024.
EXPOSURE: The study exposure was a new prescription of an SGLT2i compared to noninitiation of an SGLT2i. Inverse probability of treatment weighting by a propensity score for the receipt of SGLT2i was used to achieve balance of baseline covariates in both exposure groups.
MAIN OUTCOMES AND MEASURES: The primary study outcome was hyperkalemia, defined as a serum potassium of greater than 5.5 mEq/L or an administrative code for an inpatient or outpatient encounter with hyperkalemia within 1 year of the index date.
RESULTS: A total of 20 063 individuals who initiated an SGLT2i (mean [SD] age, 76.9 [6.6] years; 12 020 [59.9%] male) were compared to a pseudopopulation of 19 781 nonusers (mean [SD] age, 76.8 [7.0] years; 11 731 [59.3%] male). In the overall cohort, 95% had diabetes, 17% had heart failure, and 32% had stage 3 to 5 chronic kidney disease. SGLT2i initiation was associated with a lower risk of hyperkalemia (hazard ratio, 0.89 [95% CI, 0.82-0.96]). SGLT2i users had a significantly lower rate of RAASi discontinuation compared to nonusers (36% vs 45%; P < .001).
CONCLUSIONS AND RELEVANCE: This cohort study demonstrated that, among individuals with diabetes, heart failure, or chronic kidney disease who were receiving a RAASi, SGLT2i initiation was associated with a lower risk of hyperkalemia and RAASi discontinuation.
参考来源
- Wing S, Ray JG, Yau K, et al. SGLT2 Inhibitors and Risk for Hyperkalemia Among Individuals Receiving RAAS Inhibitors. JAMA Intern Med. 2025. PMID: 40293730. doi:10.1001/jamainternmed.2025.0686
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。